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Abstract
BACKGROUND
Liver cirrhosis is the late stage of hepatic fibrosis and is characterized by portal
hypertension that can clinically lead to decompensation in the form of ascites,
esophageal/gastric varices or encephalopathy. The most common sequelae
associated with liver cirrhosis are neurologic and neuropsychiatric impairments
labeled as hepatic encephalopathy (HE). Well established triggers for HE include
infection, gastrointestinal bleeding, constipation, and medications. Alterations to
the gut microbiome is one of the leading ammonia producers in the body, and
therefore may make patients more susceptible to HE.
AIM
To investigate the relationship between the use of proton pump inhibitors (PPIs)
and HE in patients with cirrhosis.
METHODS
This is a single center, retrospective analysis. Patients were included in the study
with an admitting diagnosis of HE. The degree of HE was determined from
subjective and objective portions of hospital admission notes using the West
Haven Criteria. The primary outcome of the study was to evaluate the grade of
HE in PPI users versus non-users at admission to the hospital and throughout
their hospital course. Secondary outcomes included rate of infection,
gastrointestinal bleeding within the last 12 mo, mean ammonia level, and model
for end-stage liver disease scores at admission.
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RESULTS
The HE grade at admission using the West Haven Criteria was 2.3 in the PPI
group compared to 1.7 in the PPI nonuser group (P = 0.001). The average length
of hospital stay in PPI group was 8.3 d compared to 6.5 d in PPI nonusers (P =
0.046). Twenty-seven (31.8%) patients in the PPI user group required an Intensive
Care Unit admission during their hospital course compared to 6 in the PPI
nonuser group (16.7%) (P = 0.138). Finally, 10 (11.8%) patients in the PPI group
expired during their hospital stay compared to 1 in the PPI nonuser group (2.8%)
(P = 0.220).
CONCLUSION
Chronic PPI use in cirrhotic patients is associated with significantly higher
average West Haven Criteria for HE compared to patients that do not use PPIs.
Key words: Cirrhosis; Hepatic encephalopathy; Proton pump inhibitors; Hepatology;
Proton pump inhibitor
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: In this study, we investigate whether proton pump inhibitor (PPI) use in hepatic
encephalopathy patients predisposes them to more severe stages of hepatic
encephalopathy as per West Haven Criteria. We found that chronic PPI use in cirrhotic
patients is associated with significantly higher average West Haven Criteria for hepatic
encephalopathy compared to patients that did not use PPIs. Our data also indicated that
cirrhotic patients on PPIs have longer hospital stays, with increased morbidity and
mortality during their hospital stays.
Citation: Fasullo M, Rau P, Liu DQ, Holzwanger E, Mathew JP, Guilarte-Walker Y, Szabo G.
Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients.
World J Hepatol 2019; 11(6): 522-530
URL: https://www.wjgnet.com/1948-5182/full/v11/i6/522.htm
DOI: https://dx.doi.org/10.4254/wjh.v11.i6.522
INTRODUCTION
Liver  cirrhosis  is  a  late  stage  of  hepatic  fibrosis  and  is  characterized  by  portal
hypertension  that  can  clinically  lead  to  decompensation  in  the  form  of  ascites,
esophageal/gastric varices or encephalopathy. There are multiple etiologies of liver
cirrhosis,  with  Hepatitis  C,  alcoholic  hepatitis/alcoholic  liver  disease  and  non-
alcoholic fatty liver disease being the most common causes in the developed world[1].
Some of the most common sequelae associated with liver cirrhosis are neurologic and
neuropsychiatric  impairments  labeled  as  hepatic  encephalopathy  (HE).  Neu-
ropsychiatric changes associated with liver disease were first described by Adams and
Foley in the 1940s and 1950s[2]. Since then, our understanding of what HE entails and
what precipitates it has only marginally grown. According to the currently accepted
definition, HE is a neuropsychiatric disorder that can encompass a broad spectrum of
presentations summarized in the West Haven Criteria Severity Scale. HE spans from
minimal to Grade I (mild confusion, disordered sleep), through Grades II (lethargy,
moderate confusion), III (marked confusion, incoherent speech) and finally Grade IV
(coma)[3,4].
While liver cirrhosis can predispose a patient to HE, there are additional triggers
that  can  precipitate  it  or  worsen  its  severity.  Well  established  triggers  include
infection, gastrointestinal (GI) bleeding, constipation, and medications such as opioids
and benzodiazepines[5-8]. New studies have cited other etiologies, including changes in
gut flora and small bowel bacterial overgrowth[9,10]. More recently, there have been
studies on the role of proton pump inhibitors (PPIs) in contributing to HE in cirrhotic
patients.  PPIs  are  commonly  prescribed  for  many  GI  diseases,  most  commonly
gastroesophageal reflux disease (commonly known as GERD), peptic ulcer disease,
and gastritis[11]. In contrast to previous beliefs, recent data suggests that PPIs have the
potential for multiple adverse effects. PPIs act by decreasing gastric acid secretion,
which  is  believed  to  be  protective  against  acid-related  mucosal  injury  in  the
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stomach[12]. It was thought that their ability to protect the GI mucosa would mitigate
the number of GI bleeds in cirrhotic patients, therefore reducing their risk of HE.
However, new studies show that in addition to their direct effects in the stomach, PPIs
may affect composition of the gut microbiome while also promoting small bowel
bacterial overgrowth[13].
Normally, nitrogenous compounds formed by the gut are drained into the portal
system and filtered by the liver[14]. These compounds then enter the urea cycle and are
excreted in urine.  However,  in patients with liver disease,  ammonia clearance is
compromised due to reduced liver function and increased portosystemic shunting,
leading to high levels of ammonia in the blood stream. When ammonia reaches the
brain, it is metabolized by astrocytes and transformed from glutamate to glutamine
via glutamine synthase. Accumulation of glutamine increases intracellular oncotic
pressure,  leading  to  cerebral  edema.  In  patients  with  chronic  liver  disease,  this
cerebral edema can be subtle, and at this time, the edema alone does not explain all
the findings of HE[15-17].  However, the morphological changes seen with astrocyte
swelling are similar to the changes seen in Type II Alzheimer’s disease[18]. Therefore,
given the current mechanisms, it appears that ammonia levels (and subsequently
astrocyte glutamine levels) have an overall neurotoxic effect.
Studies  have  shown  that  an  increased  gastric  pH  allows  for  increased  gut
microflora. In turn this can lead to increased bacterial translocation. Microflora species
such as Salmonella,  Campylobacter jejuni,  Escherichia coli,  Clostridium difficile,  Vibrio
cholerae and Listeria all appear to proliferate in high gastric pH[13]. In addition, the
literature suggests that more severe bacterial proliferation such as small intestinal
bacterial overgrowth has also been linked with gastric hypochlorhydria secondary to
prolonged PPI use. Overall, it does appear that elevation of gastric pH allows for
greater gut bacterial proliferation. Increased proliferation is not without consequence,
as the gut microbiome is one of the leading ammonia producers in the body, and
therefore may make patients more susceptible to HE, which is what we believe to be
the driving force behind our findings. This would partly explain why rifaximin, a
poorly absorbable synthetic antibiotic, can lower the risk of HE in cirrhotic patients by
affecting the gut microbiota. Given that changes in gut flora may lead to worse HE,
the role of PPIs must be reconsidered. This study investigates whether PPI use in HE
patients  predisposes  them  to  more  severe  stages  of  HE  as  per  the  West  Haven
Criteria.
MATERIALS AND METHODS
Patient selection
This  retrospective  medical  chart  review was  conducted at  the  UMass  Memorial
Medical Center. Records for patients who presented with acute HE between January
1, 2012 and January 1, 2016 were reviewed. Patients were included in the study with
an admitting diagnosis of HE with and without coma with ICD-9 code 572.2 and ICD-
10 codes K72.00 and K72.01.
Eligible  patients  were  ≥  18  years  of  age,  had prior  history of  End Stage Liver
Disease or cirrhosis as determined by consistent image findings and/or liver biopsy.
Patients were on PPIs for a minimum of 30 d prior to hospital admission. Exclusion
criteria included pregnancy, current prisoner, failure to sign consent, and concomitant
diagnosis of human immunodeficiency virus.
Data collection
Utilizing medical record and data from Electronic Health Records, demographics
(age, sex), grade of HE, Model End Stage Liver Disease (MELD) score, Length of stay,
etiology of cirrhosis, concomitant infection, ammonia level, history of bleeding in the
last 12 mo, etiology of HE, intensive care unit (ICU) stay, and patient expiration, were
collected. The degree of HE was determined from subjective and objective portions of
hospital admission notes using the West Haven Criteria. Grade I included lack of
trivial awareness, presence of euphoria and/or anxiety, shortened attention span
and/or  altered  sleep  rhythm.  Patients  met  Grade  II  if  they  were  lethargic,  had
personality changes, disorientation to time, dyspraxia and/or asterixis on physical
exam.  Grade  III  encephalopathy  included  confusion,  disorientation  to  space,
somnolence or signs of semi-stupor. Finally,  Grade IV was defined as coma. The
institutional  review board  at  UMass  Medical  School/UMass  Memorial  Medical
Center approved this study.
Definition of events and study outcomes
The primary outcome of the study was to evaluate the grade of HE in PPI users versus
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non-users at  the time of admission to the hospital  and throughout their  hospital
course. Secondary outcomes included rate of infection, GI bleeding within the last 12
mo, mean ammonia level, and MELD scores at admission.
Statistical analysis
Data was analyzed using R version 3.3.2 GUI 1.68 Mavericks built for Mac computer.
The statistical significance of between-cohort differences in categorical variables was
tested using the chi-square test and in continuous variables using the two-sample t-
test.  All  tests  were  two-tailed with a  significance  level  of  P  <  0.05.  Multivariate
analysis  using a  linear  regression model  was applied to  primary and secondary
endpoints to determine statistically significant differences between PPI users and non-
users. The threshold for statistical significance was set at P values < 0.05.
RESULTS
Demographics and clinical characteristics
A total of 103 patients were included in this study from UMass Memorial Medical
Center between January 2013 and December 2016. All patients had been diagnosed
with liver cirrhosis based on imaging studies (U/S, computer scanning or magnetic
resonance imaging) or liver biopsy and evidence of portal hypertension based on
clinical signs, imaging or portal pressure measurement. Seventy-five (73%) of these
cirrhosis patients were taking PPIs (PPI user), while twenty-eight (27%) patients with
cirrhosis were not taking PPIs prior to enrollment (PPI non-user). The mean age of
patients included in this study was 58.3 years, with the PPI user group being 59.6
years and in the PPI nonuser group being 55.3 years (P =  0.044).  With regards to
gender, males represented 54 (63.5%) patients in the PPI user group and 17 (47.2%) in
PPI nonuser group (P = 0.143). Sixty-three (74.1%) patients were on lactulose in the
PPI user group compared to 9 (80%) in the PPI nonuser group (P = 0.599).
Primary outcomes
The primary outcomes of this study were the grade of HE and hospital course for PPI
users compared to non-users. The grade of HE using the West Haven Criteria was 2.3
in the PPI group compared to 1.7 in the PPI nonuser group, which represented a
statistically significant difference (P = 0.001) (Table 1). With regards to hospital course,
several outcomes were analyzed. The average length of hospital stay in the PPI group
was 8.3  d compared to 6.5  d in PPI nonusers (P =  0.046).  Twenty-seven patients
(31.8%) in the PPI user group required an ICU admission during their hospital course
compared to  6  in  the  PPI  nonuser  group (16.7%) (P =  0.138).  Finally,  10  (11.8%)
patients in the PPI group expired during their hospital stay compared to 1 in the PPI
nonuser group (2.8%) (P = 0.220).
Secondary outcomes
Several secondary outcomes including infections, serum ammonia levels, MELD and
GI bleeding were measured to further determine the effects of long-term PPI use in
the cirrhotic population. With regards to infections, 5 patients (5.9%) in the PPI group
developed Clostridium difficile  compared to 0 in the PPI nonuser group (0%) (P =
0.324). Ten patients (11.8%) of the PPI group developed pneumonia compared to 1 in
the PPI nonuser group (2.8%) (P = 0.220). Five patients in the PPI group developed
spontaneous bacterial peritonitis compared to 4 in the PPI nonuser group (11.1%) (P =
0.533). The mean ammonia level of the PPI group on admission to the hospital was
significantly higher, 67.8 mg/dL compared to 45.5 mg/dL in the PPI non-user group
(P = 0.095). The mean MELD for the PPI group was 19.7 compared to 20.3 in the PPI
nonuser  group  (P  =  0.687).  Twenty-six  patients  (30.6%)  in  the  PPI  group  were
admitted to the hospital for a GI bleed within the year prior to admission compared to
13 (36%) in the PPI nonuser group (P = 0.703) (Table 2).
Linear regression model
The multiple linear regression models showed that PPI use was associated with a
higher grade of HE in cirrhosis compared to no PPI use. After adjustment for age, sex,
MELD score, and lactulose use, the association between PPI use and HE grade was
maintained (P < 0.001), with a beta of 0.607 and standard error of 0.179. In addition, a
higher MELD score was also associated with a higher HE grade, with a beta of 0.024
and standard error of 0.011 (P = 0.041) (Table 3).
DISCUSSION
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Table 1  Grade of hepatic encephalopathy in proton pump inhibitor users versus nonusers
Grade of HE
PPI user PPI nonuser
n = 75 n = 28
Grade 1 15 (20.0) 11 (39.3)
Grade 2 32 (46.6) 13 (46.4)
Grade 3 18 (24.0) 4 (14.3)
Grade 4 10 (13.4) 0 (0)
n (%), Grade of hepatic encephalopathy (HE) is defined by the West Haven Criteria Severity Scale for HE:
Grade  I  (mild  confusion,  disordered  sleep),  II  (lethargy  moderate  confusion),  III  (marked  confusion,
incoherent speech), IV (coma). HE: Hepatic encephalopathy; PPI: Proton pump inhibitor.
Because of their effectiveness in suppressing gastric acid secretions, PPIs have become
one of the most commonly prescribed drug classes with annual expenditures in 2009
estimated at $13 billion in the United States and $24 billion worldwide[19]. The first PPI
available was omeprazole [Prilosec, Prilosec OTC, Zegerid, Zegerid OTC Losec in
Canada], which served as a basis for all other PPIs in its mechanism of action by
causing irreversible  inhibition of  H+/K+  ATPase,  therefore halting hydrogen ion
expulsion into the gastric lumen. While many studies have confirmed PPIs to be safe,
our  study indicates  that  in  cirrhosis  patients,  the  use  of  PPIs  is  associated with
worsened hospital outcomes.
In  this  study,  we  found  that  hospitalized  cirrhotic  patients  on  a  PPI  had  a
significantly higher average West Haven Criteria for HE (score of 2.3) compared to
patients who were not on a PPI (scored an average of 1.7, P = 0.001). Using linear
regression models, we showed that patients using PPIs had a higher West Haven
Criteria grade HE regardless of age, sex, MELD score, and/or lactulose use. Other
statistically  significant  differences  between  the  PPI  user  and  non-user  groups
included longer length of hospital stay (8.5 d for PPI users vs 6.5 for PPI nonusers, P =
0.046). In alignment with patients having a higher grade of HE as well as a longer
length of hospital stay, a greater percentage of patients in the PPI user group also had
an ICU admission, indicating the greater extent of systemic involvement in this group.
A recent meta-analysis by Bian et al[20] supports our contention that there is a higher
risk of developing HE in PPI users with liver dysfunction.
Prior studies have also indicated that PPI use could worsen HE in cirrhotic patients.
A dose response analysis by Tsai et al[21] stratified patients based on length of PPI use
and showed that  longer  PPI  use  led  to  higher  rates  of  HE.  The  result  remained
statistically significant after adjustment of patient comorbidities. Hung et al[22] showed
that cirrhotic patients on a PPI with HE had higher mortality rates at 30 d, 90 d and
one year compared to cirrhotic patients with HE not on PPIs. This study investigates
whether PPI use in HE patients predisposes them to more severe stages of HE as
defined by the West Haven Criteria. Our analysis shows that patients on a PPI had
significantly higher West Haven Criteria scale episode of HE compared to those not
on a PPI (2.3 vs  1.7, P  = 0.001). In addition, our study shows that PPIs predispose
cirrhotic patients towards worsened encephalopathy regardless of age, sex, MELD
score, or lactulose use.
The exact pathophysiology of HE is still not fully understood. Multiple mechanisms
of action have been hypothesized and investigated, including the role of ammonia,
increased GABA receptors in the brain, and accumulation of endogenous opioids[23].
Overall, it appears that HE is multifactorial, with accumulation of ammonia being a
leading cause of overt HE[24]. In fact, studies have shown that HE ammonia levels are
increased in 90% of patients. The primary source of ammonia in the body is the GI
tract as a byproduct of chronic bacterial colonization, by enterocytes as they transform
glutamine into ammonia, and by H. pylori, which metabolizes urea into ammonia.
However, H. pylori’s role in HE is still unclear[25,26].
One of the secondary endpoints in this study was determining the risk for infection
in patients with cirrhosis on a PPI. Our data shows that patients on a PPI may have
higher rates of C. difficile infection, pneumonia and spontaneous bacterial peritonitis.
However, these results were not statistically significant with P-values of 0.324, 0.220
and 0.533, respectively. This is thought to be due to this study’s small sample size of
103  patients.  A recent  meta-analysis  by Lambert  et  al[27]  again  demonstrated the
association of community acquired pneumonia and Clostridium difficile-associated
diarrhea  (CDAD)  with  the  use  of  PPI.  The  most  likely  pathogenesis  of  the
development of these infections has been attributed to direct acid suppression in the
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Table 2  Participant characteristics
Variables Total, n = 103 PPI user, n = 75 PPI nonuser, n = 28 P value
Age, yr, Mean ± SD 58.3 (10.8) 59.6 (10.6) 55.3 (10.7) 0.044a
Sex, male, n (%) 71 (58.7) 54 (63.5) 17 (47.2) 0.143
On lactulose, n (%) 92 (76) 63 (74.1) 29 (80) 0.599
Bleeding in last 12 mo, n (%) 39 (32.2) 26 (30.6) 13 (36.1) 0.703
Infection, n (%)
Clostridium difficile colitis 5 (4.1) 5 (5.9) 0 (0) 0.324
   Pneumonia 11 (9.1) 10 (11.8) 1 (2.8) 0.220
   Spontaneous bacterial peritonitis 9 (7.4) 5 (5.9) 4 (11.1) 0.533
Serum ammonia level, Mean ± SD 61.1 (67.2) 67.8 (67.8) 45.5 (64.2) 0.095
Grade of hepatic encephalopathy, Mean ± SD 2.1 (0.9) 2.3 (0.9) 1.7 (0.7) 0.001b
MELD score, Mean ± SD 19.9 (7.2) 19.7 (7.4) 20.3 (6.7) 0.687
Length of stay in d, Mean ± SD 8.5 (7.0) 8.3 (7.9) 6.5 (3.7) 0.046a
Required ICU, n (%) 33 (27.3) 27 (31.8) 6 (16.7) 0.138
Expired, n (%) 11 (9.1) 10 (11.8) 1 (2.8) 0.220
aP < 0.05,
bP < 0.01. MELD: Model for end-stage liver disease; ICU: Intensive care unit.
stomach and small bowel. With regards to CDAD, Janarthanan et al[28] suggested that
the alkaline status of the stomach (pH > 5) likely predisposes the patient to enhanced
survival  of  C.  difficile  vegetative  spores.  A recent  study in  2018 by Naito  et  al[29]
confirms our notion that continued PPI use leads to intestinal dysbiosis. Using 16S
rRNA gene sequencing,  PPIs were found to significantly increase certain enteric
microbe taxonomy, including Streptococcaceae  and Enterococcaceae,  which are risk
factors for CDAD, and to decrease Faecalibacterium, a commensal anti-inflammatory
microbe present in human models.
Our paper has several limitations. First, because it is a retrospective review, in-
formation collection is  incomplete,  particularly  regarding follow-up evaluation.
Secondly because, we had an uneven distribution of the number of patients in the PPI
use and non-use groups. Finally, due to the small sample size used for our study,
several of our secondary outcomes were not statistically significant, including several
infections and ICU admission rate, likely secondary to a lack of power. Again, as with
any retrospective study, it is important to note that this type of study is unable to
define exact causality. Further randomized, controlled, prospective studies are needed
to help confirm the observation seen in our study.
In  conclusion,  PPIs  are  commonly prescribed for  many GI  diseases  including
GERD, peptic ulcer disease, and gastritis. They are often used without regard for their
adverse effects. Our study demonstrates that PPI use in cirrhotic patients is associated
with more severe degree of HE compared to those not on a PPI. Our data also showed
that PPI use in this population was associated with a longer hospital stay and higher
percentage of patients requiring an ICU admission. We suggest reducing PPI use in
the cirrhotic population as a means to reduce episodes of HE. Further randomized-
controlled, prospective studies are needed to help confirm this observation.
WJH https://www.wjgnet.com June 27, 2019 Volume 11 Issue 6
Fasullo M et al. PPIs worsen hepatic encephalopathy
527
Table 3  Linear regression models, grade of hepatic encephalopathy
Variables Β ± SE P value
Model 1, demographic variables
   Age -0.001 ± 0.001 0.871
   Sex 0.062 ± 0.167 0.710
   PPI use 0.607 ± 0.180 0.001b
Model 2, medical comorbidities
   Age 0.002 ± 0.008 0.787
   Sex 0.043 ± 0.166 0.797
   MELD Score 0.020 ± 0.011 0.079
   PPI Use 0.607 ± 0.179 < 0.001b
Model 3, other medications
   Age 0.004 ± 0.008 0.647
   Sex 0.033 ± 0.164 0.839
   MELD Score 0.024 ± 0.011 0.041a
   Lactulose 0.324 ± 0.189 0.089
   PPI use 0.625 ± 0.178 < 0.001b
aP < 0.05,
bP < 0.01. B ± SE: beta ± standard error. MELD: Model for end-stage liver disease; PPI: Proton pump inhibitor.
ARTICLE HIGHLIGHTS
Research background
Proton  pump  inhibitors  (PPIs)  are  a  recent  hot  topic  in  both  internal  medicine  and  gas-
troenterology, mostly because of their widespread use. Studies are quickly demonstrating that
these medications may not come without risk,  as recent studies have demonstrated a clear
association between PPI and conditions like osteoporosis, pneumonia, Clostridium difficile, and
some even postulate  an association with dementia.  While  many effects  of  PPIs  are  still  in
question, it has also been shown that PPIs work by acid suppression, which can disrupt the gut
microbiome.  Patients  with  cirrhosis  are  at  risk  to  develop  hepatic  encephalopathy  (HE),
primarily through ammonia produced by typical gut flora, and could subsequently be at risk for
changes in this condition if the microbiome is altered in any way.
Research motivation
The main topic we are trying to address is whether PPI overuse can lead to additional effects
aside  from  those  previously  mentioned  and  described  in  the  literature.  One  particularly
vulnerable population is those with cirrhosis, as ammonia production is affected by the gut
microbiome. Solving this problem would allow future therapeutics to focus on the gut-liver-
microbiome axis to prevent or lessen the severity of HE.
Research objectives
The main objective we want to demonstrate is the effect of PPI on the degree of HE. We hope to
draw an association between PPIs and HE to encourage further prospective research studies on
the side effects of PPIs, the gut microbiome in relation to HE, and to further aid in hospital
outcomes for patients with cirrhosis.
Research methods
This is a retrospective analysis of patients with liver cirrhosis who were admitted with an ICD-9
and/or  ICD-9  diagnosis  of  HE.  Once  these  patients  were  identified,  a  chart  analysis  was
performed to  determine  if  these  patients  were  on  a  PPI  for  >  30  d  prior  to  their  hospital
admission. Those who were on a PPI for > 30 d were compared to patients who were not on a
PPI at all in relation to their hospital stay. A linear regression model was applied to all patients
to confirm the absence of any confounding variables.
Research results
During our analysis, we found that patients on a PPI who were admitted with HE subsequently
had a significantly longer hospital stay, significantly worse grade of HE, and a larger percentage
of those had intensive care unit (commonly known as ICU) admissions during their hospital
stay. These findings suggest that patients should be assessed for the need for PPIs at every visit.
This also points to the gap in knowledge between PPI and HE, especially if future research is
able to demonstrate changes in the gut microbiome in patients on PPIs.
Research conclusions
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In summary, in this retrospective medical chart review, PPI use was shown to be associated with
worsened HE, greater length of hospital stays, and higher rate of ICU admissions in cirrhotic
patients. To our knowledge, this is the first study that demonstrated that PPI use is associated
with worse grades of HE, whereas prior studies by Tsai et al and Hung et al demonstrated higher
risk of HE and overall higher mortality, respectively, in an Asian population. We propose that
PPI use might affect cirrhotic patients by altering gastric pH, leading to the proliferation of gut
micro-biome, thereby increasing ammonia production and bacterial translation. Considering the
recent increased prevalence of PPIs, this study provides clinically relevant information regarding
their potential risks in the cirrhotic population.
Research perspectives
As a  retrospective  review,  our  study is  limited by incomplete  data  collection and uneven
distribution  of  PPI  user  and  non-user  groups.  However,  the  observation  that  PPI  users
experience worsen HE and longer hospital stays is clinically important. Future randomized-
controlled studies will help confirm this observation and guide clinicians in a shift away from
the use of PPI in cirrhotic patients.
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